Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma
暂无分享,去创建一个
Christopher M. Jackson | D. Pardoll | H. Brem | B. Tyler | T. Garzon-Muvdi | M. Lim | A. Luksik | Z. Belcaid | S. Ganguly | Eileen S Kim | R. Maxwell | D. Theodros | Russell Maxwell
[1] J. Huse,et al. Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy , 2017, Neuro-oncology.
[2] Z. Guo,et al. Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy , 2017, Nature Communications.
[3] M. Sweet,et al. The toll-like receptor 3 pathway in homeostasis, responses to injury and wound repair. , 2017, Seminars in cell & developmental biology.
[4] Christopher M. Jackson,et al. Anti–PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM , 2016, Science Translational Medicine.
[5] P. Benaroch,et al. TLR3-Induced Maturation of Murine Dendritic Cells Regulates CTL Responses by Modulating PD-L1 Trafficking , 2016, PloS one.
[6] T. Schumacher,et al. Genomics- and Transcriptomics-Based Patient Selection for Cancer Treatment With Immune Checkpoint Inhibitors: A Review. , 2016, JAMA oncology.
[7] L. Diaz,et al. Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade. , 2016, The oncologist.
[8] M. Weller,et al. Current State of Immune-Based Therapies for Glioblastoma. , 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[9] H. Sugiyama,et al. Biphasic function of TLR3 adjuvant on tumor and spleen dendritic cells promotes tumor T cell infiltration and regression in a vaccine therapy , 2016, Oncoimmunology.
[10] J. Taube,et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy , 2016, Nature Reviews Cancer.
[11] Z. Trajanoski,et al. Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability. , 2016, Immunity.
[12] P. Hertzog,et al. Optimizing mouse models for precision cancer prevention , 2016, Nature Reviews Cancer.
[13] Clare L. Bennett,et al. Depletion of CD11c+ cells in the CD11c.DTR model drives expansion of unique CD64+ Ly6C+ monocytes that are poised to release TNF-α , 2015, European Journal of Immunology.
[14] J. Hubbell,et al. TLR-3 stimulation improves anti-tumor immunity elicited by dendritic cell exosome-based vaccines in a murine model of melanoma , 2015, Scientific Reports.
[15] M. Weller,et al. Immunosuppressive mechanisms in glioblastoma. , 2015, Neuro-oncology.
[16] D. Hafler,et al. Prospects of immune checkpoint modulators in the treatment of glioblastoma , 2015, Nature Reviews Neurology.
[17] Timothy J Keyes,et al. Structural and functional features of central nervous system lymphatics , 2015, Nature.
[18] D. Pardoll,et al. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade , 2015, Science Translational Medicine.
[19] C. Drake,et al. Immune checkpoint blockade: a common denominator approach to cancer therapy. , 2015, Cancer cell.
[20] I. Bechmann,et al. CD11c‐positive cells from brain, spleen, lung, and liver exhibit site‐specific immune phenotypes and plastically adapt to new environments , 2015, Glia.
[21] D. Schrijvers,et al. Poly(I:C) as cancer vaccine adjuvant: knocking on the door of medical breakthroughs. , 2015, Pharmacology & therapeutics.
[22] J. Engh,et al. Induction of Robust Type-I CD8+ T-cell Responses in WHO Grade 2 Low-Grade Glioma Patients Receiving Peptide-Based Vaccines in Combination with Poly-ICLC , 2014, Clinical Cancer Research.
[23] L. Facci,et al. Toll-Like Receptors 2, -3 and -4 Prime Microglia but not Astrocytes Across Central Nervous System Regions for ATP-Dependent Interleukin-1β Release , 2014, Scientific Reports.
[24] T. Owens,et al. Comparison of microglia and infiltrating CD11c+ cells as antigen presenting cells for T cell proliferation and cytokine response , 2014, Journal of Neuroinflammation.
[25] A. Nagy,et al. Immune privilege of the CNS is not the consequence of limited antigen sampling , 2014, Scientific Reports.
[26] M. Speicher,et al. Functional Network Pipeline Reveals Genetic Determinants Associated with in Situ Lymphocyte Proliferation and Survival of Cancer Patients , 2014, Science Translational Medicine.
[27] N. Gupta,et al. In Vivo Imaging of Lymphatic Drainage of Cerebrospinal Fluid in Mouse , 2013, Fluids and Barriers of the CNS.
[28] Walter J Curran,et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] Christina S. Leslie,et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression , 2013, Nature Medicine.
[30] John Wong,et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. , 2013, International journal of radiation oncology, biology, physics.
[31] J. Ohlfest,et al. Increasing the efficacy of tumor cell vaccines by enhancing cross priming. , 2012, Cancer letters.
[32] Didier Frappaz,et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. , 2012, The Lancet. Oncology.
[33] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[34] Alison P. Klein,et al. Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape , 2012, Science Translational Medicine.
[35] Drew M. Pardoll,et al. The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.
[36] L. Norton,et al. Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. , 2012, Cancer research.
[37] B. Clarkson,et al. Innate-adaptive crosstalk: how dendritic cells shape immune responses in the CNS. , 2012, Advances in experimental medicine and biology.
[38] Christopher M. Jackson,et al. Challenges in Immunotherapy Presented by the Glioblastoma Multiforme Microenvironment , 2011, Clinical & developmental immunology.
[39] A. Cardona,et al. Isolation of brain and spinal cord mononuclear cells using percoll gradients. , 2011, Journal of visualized experiments : JoVE.
[40] B. Nelson,et al. Profound CD8+ T cell immunity elicited by sequential daily immunization with exogenous antigen plus the TLR3 agonist poly(I:C). , 2011, Vaccine.
[41] J. Engh,et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] T. Batchelor,et al. A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma. , 2010, Neuro-oncology.
[43] Edward R. Kastenhuber,et al. Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-α and IFN-γ dependent manners , 2010, Cancer Immunology, Immunotherapy.
[44] Steven Piantadosi,et al. Survival of Patients with Newly Diagnosed Glioblastoma Treated with Radiation and Temozolomide in Research Studies in the United States , 2010, Clinical Cancer Research.
[45] Zlatko Trajanoski,et al. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. , 2010, Gastroenterology.
[46] Isaac Yang,et al. The role of microglia in central nervous system immunity and glioma immunology , 2010, Journal of Clinical Neuroscience.
[47] T. Ley,et al. Interleukin 12 stimulates IFN-gamma-mediated inhibition of tumor-induced regulatory T-cell proliferation and enhances tumor clearance. , 2009, Cancer research.
[48] R. Mirimanoff,et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.
[49] M. Mason,et al. A clinical grade poly I:C-analogue (Ampligen) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro. , 2009, Vaccine.
[50] Li Wu,et al. Selective suicide of cross-presenting CD8+ dendritic cells by cytochrome c injection shows functional heterogeneity within this subset , 2008, Proceedings of the National Academy of Sciences.
[51] Susan M. Chang,et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05) , 2008, Journal of Neuro-Oncology.
[52] Susan M. Chang,et al. A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas , 2008, Journal of Neuro-Oncology.
[53] S. Akira,et al. Toll-like Receptors and Type I Interferons* , 2007, Journal of Biological Chemistry.
[54] K. Hoebe,et al. Cell-Associated Double-Stranded RNA Enhances Antitumor Activity through the Production of Type I IFN1 , 2006, The Journal of Immunology.
[55] W. Gillanders,et al. The adjuvant effects of the toll-like receptor 3 ligand polyinosinic-cytidylic acid poly (I:C) on antigen-specific CD8+ T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu. , 2006, Vaccine.
[56] D. Tough,et al. IFN-α/β-dependent cross-priming induced by specific toll-like receptor agonists , 2006 .
[57] D. Tough,et al. IFN-alpha/beta-dependent cross-priming induced by specific toll-like receptor agonists. , 2006, Vaccine.
[58] A. Friedman,et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. , 2006, Cancer research.
[59] A. Heimberger,et al. Immunotherapy for human glioma: innovative approaches and recent results , 2005, Expert review of anticancer therapy.
[60] W. Gillanders,et al. Defining the Antigen-Specific T-Cell Response to Vaccination and Poly(I:C)/TLR3 Signaling: Evidence of Enhanced Primary and Memory CD8 T-Cell Responses and Antitumor Immunity , 2005, Journal of immunotherapy.
[61] A. Palucka,et al. Dendritic cells as therapeutic vaccines against cancer , 2005, Nature Reviews Immunology.
[62] G. Zhu,et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. , 2005, Cancer research.
[63] C. Barcia,et al. Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.
[64] D. Tough,et al. Shaping of adaptive immune responses to soluble proteins by TLR agonists: A role for IFN‐α/β , 2004, Immunology and cell biology.
[65] G. Belz,et al. Cross‐presentation, dendritic cell subsets, and the generation of immunity to cellular antigens , 2004, Immunological reviews.
[66] Helga E de Vries,et al. The Blood‐Brain Barrier and Its Role in Immune Privilege in the Central Nervous System , 2003, Journal of neuropathology and experimental neurology.
[67] F. Belardelli,et al. IL-15 Is Expressed by Dendritic Cells in Response to Type I IFN, Double-Stranded RNA, or Lipopolysaccharide and Promotes Dendritic Cell Activation1 , 2001, The Journal of Immunology.
[68] A. Ommaya,et al. Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: an open pilot study. , 1996, Neurosurgery.
[69] P. Knopf,et al. Role of cervical lymph nodes in the systemic humoral immune response to human serum albumin microinfused into rat cerebrospinal fluid , 1989, Journal of Neuroimmunology.